VNDA Vanda Pharmaceuticals Inc.

20.8
+0.77  (+4%)
Previous Close 20.03
Open 20.44
Price To Book 4.18
Market Cap 1090957504
Shares 52,449,880
Volume 1,106,339
Short Ratio
Av. Daily Volume 938,946

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2Q 2019.
Tradipitant
Gastroparesis
PK trial initiated with full enrollment completed 4Q 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
PDUFA date August 16, 2019.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 3 data released December 10, 2018 - one of two primary endpoints met. sNDA filing due 3Q 2019.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3 data due 1H 2020.
Tradipitant
Atopic dermatitis
Phase 1 initiated October 2018.
VTR-297
Hematologic malignancies
Phase 2 data due 2Q 2019.
Tradipitant
Motion sickness

Latest News

  1. VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm
  2. Lifshitz & Miller LLP Announces Investigation of Bristow Group Inc., Helius Medical Technologies, Inc., Nordstrom Inc., PriceSmart, Inc., Ryanair Holdings plc, Solid Biosciences Inc., and Vanda Pharmaceuticals Inc.
  3. EQUITY ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Vanda Pharmaceuticals Inc.; Investors are Encouraged to Contact the Firm – VNDA
  4. New Research: Key Drivers of Growth for Arconic, Vanda Pharmaceuticals, Avaya, Sempra Energy, Forward Industries, and Alamo Group — Factors of Influence, Major Initiatives and Sustained Production
  5. Glancy Prongay & Murray LLP Announces Investigation on Behalf of Vanda Pharmaceuticals Inc. Investors
  6. Edited Transcript of VNDA earnings conference call or presentation 13-Feb-19 9:30pm GMT
  7. 3 Top Growth Stocks to Buy Right Now
  8. Here's Why Vanda Pharmaceuticals Gained as Much as 11.1% Today
  9. ONGOING INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  10. The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial
  11. Vanda Pharmaceuticals Inc (VNDA) Q4 2018 Earnings Conference Call Transcript
  12. Vanda Pharmaceuticals (VNDA) Tops Q4 Earnings and Revenue Estimates
  13. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Vanda Pharmaceuticals Inc. Investors (VNDA)
  14. Vanda: 4Q Earnings Snapshot
  15. Vanda Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results
  16. INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  17. Vanda Pharmaceuticals Inc. to Host Earnings Call